Kenneth L. Davis

Q: What Schools Are Affiliated With Kenneth L. Davis

Kenneth L. Davis is affiliated with the following schools: Icahn School of Medicine at Mount Sinai, Stanford University

Kenneth L. Davis's AcademicInfluence.com Rankings

Kenneth L. Davis

Philosophy

#3071

World Rank

#5046

Historical Rank

Logic

#936

World Rank

#1520

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Kenneth L. Davis's Degrees

Bachelors Chemistry Dartmouth College

Why Is Kenneth L. Davis Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kenneth L. Davis's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Biological Insights From 108 Schizophrenia-Associated Genetic Loci (2014) (6445)
A new rating scale for Alzheimer's disease. (1984) (3825)
Dopamine in schizophrenia: a review and reconceptualization. (1991) (1967)
Mapping autism risk loci using genetic linkage and chromosomal rearrangements (2007) (1382)
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. (2000) (1308)
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia (2001) (1197)
A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects: CNV Analysis Group and the Schizophrenia Working Group of the Psychiatric Genomics Consortium (2016) (1125)
Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. (1989) (1116)
Cholinesterase Inhibitors in Alzheimer's Disease (1994) (959)
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. (2003) (920)
White matter changes in schizophrenia: evidence for myelin-related dysfunction. (2003) (778)
Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects (2016) (736)
Neuropsychopharmacology : The Fifth Generation of Progress (2002) (703)
A psychobiological perspective on the personality disorders. (1991) (669)
Neurochemical Correlates of Dementia Severity in Alzheimer's Disease: Relative Importance of the Cholinergic Deficits (1995) (573)
Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes (2017) (517)
Overview: toward a dysregulation hypothesis of depression. (1985) (510)
Cholinergic markers in elderly patients with early signs of Alzheimer disease. (1999) (510)
Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. (1995) (506)
The pathophysiology of schizophrenia disorders: perspectives from the spectrum. (2004) (448)
Physostigmine: improvement of long-term memory processes in normal humans. (1978) (442)
The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. (1983) (440)
A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. (1994) (426)
Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia (2003) (398)
Lymphocyte function in major depressive disorder. (1984) (385)
Mapping genomic loci implicates genes and synaptic biology in schizophrenia (2022) (361)
Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. (1998) (340)
Evidence for a susceptibility gene for autism on chromosome 2 and for genetic heterogeneity. (2001) (340)
Inflammatory mechanisms in Alzheimer's disease: implications for therapy. (1994) (311)
Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. (1998) (302)
CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy (2008) (297)
Positive and negative symptoms in schizophrenia (1984) (293)
Dopamine Receptor mRNA Expression in Human Striatum and Neocortex (1996) (284)
Handbook for clinical memory assessment of older adults (1986) (267)
Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. (1982) (264)
Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. (1994) (256)
Cortisol and Alzheimer's disease, I: Basal studies. (1986) (251)
Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia (2011) (245)
Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients (1999) (230)
Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. (2000) (226)
Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias. (1986) (226)
Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. (2001) (224)
Oral physostigmine treatment of patients with Alzheimer's disease. (1985) (222)
Diffusion tensor imaging findings in first-episode and chronic schizophrenia patients. (2008) (222)
Characteristics of very poor outcome schizophrenia. (1987) (217)
Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. (1999) (216)
Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: A gene ontology study (2005) (215)
Strong synaptic transmission impact by copy number variations in schizophrenia (2010) (213)
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. (2001) (212)
Depression and immunity. Lymphocyte function in ambulatory depressed patients, hospitalized schizophrenic patients, and patients hospitalized for herniorrhaphy. (1985) (208)
Ventricular Enlargement in Poor-Outcome Schizophrenia (1998) (203)
Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. (2001) (193)
Myelination, oligodendrocytes, and serious mental illness (2014) (192)
Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism. (2004) (187)
Molecular and Cellular Evidence for an Oligodendrocyte Abnormality in Schizophrenia (2002) (187)
Plasma homovanillic acid concentration and the severity of schizophrenic illness. (1985) (182)
Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients (2006) (176)
A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia (1995) (176)
Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. (2005) (174)
The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease (1997) (173)
Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. (1998) (172)
Phenytoin treatment of the binge-eating syndrome. (1977) (171)
Familial aggregation in Alzheimer's disease (1988) (169)
Cholinergic approaches to the treatment of Alzheimer's disease. (1986) (162)
Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. (1993) (158)
A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. (1988) (154)
Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. (1997) (154)
Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia (2005) (148)
Cortisol and Alzheimer's disease, II: Dexamethasone suppression, dementia severity, and affective symptoms. (1986) (146)
Homovanillic acid measurement in clinical research: a review of methodology. (1992) (146)
Pharmacologic strategies for augmenting cognitive performance in schizophrenia (1999) (145)
Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia (2007) (144)
The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease (1999) (143)
Choline in tardive dyskinesia and Huntington's disease. (1976) (143)
Alzheimer's disease. Morbid risk among first-degree relatives approximates 50% by 90 years of age. (1987) (142)
Functional Decline in Alzheimer's Disease: A Longitudinal Study (1993) (140)
Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease (2006) (138)
Treatment of schizophrenia 1999 (1999) (136)
Variations in differential gene expression patterns across multiple brain regions in schizophrenia (2005) (135)
Dementia with coexistent major depression. (1989) (135)
Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients. (1990) (133)
Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. (1997) (132)
Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia (2006) (125)
Cysteamine-induced depletion of central somatostatin-like immunoactivity: effects on behavior, learning, memory and brain neurochemistry (1987) (125)
Physostigmine in mania. (1978) (123)
A family history study of schizophrenia-related personality disorders. (1984) (122)
Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. (2003) (121)
Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: Negative symptoms (1992) (121)
Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. (1993) (120)
Pharmacological alleviation of cholinergic lesion induced memory deficits in rats. (1985) (120)
Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. (1997) (118)
Postmortem studies in schizophrenia. (1998) (114)
Convergence of cognitive and adaptive decline in late-life schizophrenia (1999) (113)
Age and the dexamethasone suppression test in depression. (1984) (110)
Gender differences in poor outcome patients with lifelong schizophrenia. (2001) (109)
Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. (1991) (107)
Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia (2003) (107)
Genetic correlation between amyotrophic lateral sclerosis and schizophrenia (2017) (107)
Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. (2007) (107)
Guanfacine Treatment of Cognitive Impairment in Schizophrenia (2001) (105)
Cholinergic underactivity in human memory disorders. (1978) (103)
Noncognitive Disturbances in Alzheimer's Disease: Frequency, Longitudinal Course, and Relationship to Cognitive Symptoms (1997) (103)
Brain Metabolite Abnormalities in the White Matter of Elderly Schizophrenic Subjects: Implication for Glial Dysfunction (2007) (103)
Psychiatric Illness in First-Degree Relatives of Patients with Paranoid Psychosis, Schizophrenia and Medical Illness (1985) (102)
Severe cognitive impairment in elderly schizophrenic patients: A clinicopathological study (1993) (100)
Brain Acetylcholine and Neuropsychiatric Disease (1979) (100)
Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. (1978) (99)
Caudate and putamen volumes in good and poor outcome patients with schizophrenia (2003) (99)
GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia (2004) (99)
Correlates of lateral ventricular size in chronic schizophrenia, I: Behavioral and treatment response measures. (1986) (96)
The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia (2000) (96)
Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. (2002) (95)
The search for disease-modifying treatment for Alzheimer's disease (1997) (93)
Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. (1988) (93)
The human homolog of the QKI gene affected in the severe dysmyelination "quaking" mouse phenotype: downregulated in multiple brain regions in schizophrenia. (2006) (93)
Correlation Between Aβx-40–, Aβx-42–, and Aβx-43–Containing Amyloid Plaques and Cognitive Decline (2001) (92)
Developing novel treatments for mood disorders: accelerating discovery (2002) (92)
Complement genes contribute sex-biased vulnerability in diverse illnesses (2020) (92)
Subtypes of depression based on excretion of MHPG and response to nortriptyline. (1980) (92)
Abnormal Indices of Cell Cycle Activity in Schizophrenia and their Potential Association with Oligodendrocytes (2008) (92)
A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples. (2012) (89)
Induction of depression with oxotremorine in patients with Alzheimer's disease. (1987) (88)
β-Endorphin and Schizophrenia (1980) (87)
9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics. (1989) (87)
Patterns of risk in first-degree relatives of patients with Alzheimer's disease. (1994) (86)
Restoration of cholinomimetic activity by clonidine in cholinergic plus noradrenergic lesioned rats (1990) (86)
Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients (2000) (85)
Familial aggregation in Alzheimerʼs disease: comparison of risk among relatives of early- and late-onset cases, and among male and female relatives in successive generations (1988) (85)
The effects of diet and physical activity on plasma homovanillic acid in normal human subjects (1983) (84)
Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. (1997) (84)
RS 86 in the treatment of alzheimer's disease: Cognitive and biological effects (1987) (84)
Molecular and genetic evidence for abnormalities in the nodes of Ranvier in schizophrenia. (2012) (84)
Diffusion Tensor Imaging in Schizophrenia (2006) (83)
The genetics and biochemistry of paranoid schizophrenia and other paranoid psychoses. (1981) (81)
The effects of hypertension and body mass index on cognition in schizophrenia. (2010) (81)
Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene (2008) (81)
AMPA Receptor Binding and Subunit mRNA Expression in Prefrontal Cortex and Striatum of Elderly Schizophrenics (1998) (80)
Neuropeptide abnormalities in patients with early Alzheimer disease. (1999) (79)
Abnormal Kainate Receptor Expression in Prefrontal Cortex in Schizophrenia (2001) (79)
Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. (2004) (78)
Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. (1991) (77)
Letter: Choline for tardive dyskinesia. (1975) (77)
Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus (2000) (76)
Excretion of MHPG in normal subjects: implications for biological classification of affective disorders. (1978) (76)
Partial reversal of lesion-induced deficits in cortical cholinergic markers by nerve growth factor (1986) (76)
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex (1996) (75)
Premorbid sociosexual functioning and long-term outcome in schizophrenia. (1989) (74)
Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. (2000) (74)
Correlates of change in functional status of institutionalized geriatric schizophrenic patients: focus on medical comorbidity. (2002) (74)
Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia (2005) (74)
Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia (2001) (74)
CSF beta-amyloid, cognition, and APOE genotype in Alzheimer’s disease (1999) (71)
Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls (2007) (70)
Cortical cholinergic markers in schizophrenia (1994) (69)
4-Aminopyridine in the treatment of alzheimer's disease (1988) (66)
Serotonin function and treatment response to clozapine in schizophrenic patients. (1993) (66)
Single case study. Possible organophosphate-induced parkinsonism. (1978) (66)
Tardive dyskinesia and depressive illness. (1976) (65)
Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? (1992) (65)
Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function (1994) (64)
The course of functional decline in geriatric patients with schizophrenia: cognitive-functional and clinical symptoms as determinants of change. (2003) (62)
A Study of the Reliability of the Family History Method in Genetic Sudies of Alzheimer Disease (1989) (62)
Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. (1996) (62)
The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. (2001) (61)
Control of exogenous factors affecting plasma homovanillic acid concentration (1987) (60)
Evidence of a locus for schizophrenia and related disorders on the short arm of chromosome 5 in a large pedigree. (1996) (60)
Cholinergic modulation of memory in rats (2004) (60)
A Comparison of Ten Polygenic Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts (2020) (60)
Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry. (2003) (60)
Enhancement of memory by physostigmine. (1979) (60)
Clinical Studies of the Cholinergic Deficit in Alzheimer's Disease (1985) (60)
Dopamine autoreceptor and postsynaptic receptor blocking potency of neuroleptics. (1982) (59)
Attentional markers of vulnerability to schizophrenia: Performance of medicated and unmedicated patients and normals (1990) (59)
L-dopa challenge and relapse in schizophrenia. (1987) (59)
Lithium's effect of parathyroid hormone. (1981) (58)
Determination of 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) in cerebrospinal fluid. (1971) (58)
Attenuation of nucleus basalis of Meynert lesion-induced cholinergic deficits by nerve growth factor (1989) (57)
Thyrotropin-releasing hormone in schizophrenia. (1975) (57)
Possible contributions of myelin and oligodendrocyte dysfunction to schizophrenia. (2004) (57)
Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. (1991) (57)
Clinical Studies of the Cholinergic Deficit in Alzheimer's Disease (1985) (56)
The relationship between apolipoprotein E, dementia, and vascular illness. (1998) (55)
Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia (1993) (55)
Antemortem markers of Alzheimer's disease (1986) (55)
Choline chloride treatment of memory deficits in the elderly. (1979) (55)
CKholinergic mechanisms and anterior pituitary hormone secretion. (1980) (55)
Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. (1993) (55)
Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease. (2005) (55)
Global expression-profiling studies and oligodendrocyte dysfunction in schizophrenia and bipolar disorder (2003) (54)
(+/-)-9-Amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity. (1988) (54)
Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer's disease and normals. (1983) (53)
Neurobehavioral deficits in Persian Gulf veterans: Evidence from a population-based study (1999) (53)
Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas (2000) (53)
Schizophrenia-related and affective personality disorder traits in relatives of probands with schizophrenia and personality disorders. (1993) (53)
Cholinergic drugs in Alzheimer's disease. (1986) (52)
Olfactory identification deficits in relatives of Alzheimer's disease patients (1996) (51)
Relationship of cognitive functioning, adaptive life skills, and negative symptom severity in poor-outcome geriatric schizophrenia patients. (2000) (51)
Is there a limbic system equivalent of tardive dyskinesia? (1979) (51)
Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients. (1987) (51)
Deterioration on the blessed test in Alzheimer's disease: Longitudinal data and their implications for clinical trials and identification of subtypes (1992) (50)
Clinical symptoms associated with age at onset in Alzheimer's disease. (1994) (50)
A pilot study of prednisone in Alzheimer's disease. (1996) (50)
Mitochondrial enzymes in schizophrenia (2007) (48)
Cholinergic imbalance hypotheses of psychoses and movement disorders: strategies for evaluation. (1975) (48)
Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. (2005) (48)
Platelet [3H]Imipramine binding in psychiatric disorders (1987) (48)
Development of cholinergic drugs for the treatment of Alzheimer's disease (1985) (47)
Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms (1991) (47)
Age-dependent expression of familial risk in Alzheimer's disease. (1988) (47)
Lateral ventricular enlargement in schizophrenic probands and their siblings with schizophrenia-related isorders (1998) (47)
Seasonal variations of human lumbar CSF neurotransmitter metabolite concentrations (1984) (46)
Immunoglobulin studies in patients with psychiatric diseases. (1985) (46)
Influence of age and relative weight on cortisol suppression in normal subjects. (1987) (45)
Cognitive and functional changes with aging in schizophrenia (1999) (45)
Temporal characteristics of tract-specific anisotropy abnormalities in schizophrenia (2008) (44)
Effects of mesocortical dopaminergic lesions upon subcortical dopaminergic function. (1988) (44)
Expression of mutant human DISC1 in mice supports abnormalities in differentiation of oligodendrocytes (2011) (43)
Short-term haloperidol administration acutely elevates human plasma homovanillic acid concentration. (1987) (42)
Cholinergic involvement in mental disorders. (1978) (42)
The validity of the family history method for identifying Alzheimer disease. (1997) (42)
CSF Somatostatin in alzheimer's disease, depressed patients, and control subjects (1988) (41)
82-kDa choline acetyltransferase is in nuclei of cholinergic neurons in human CNS and altered in aging and Alzheimer disease (2007) (41)
Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. (2001) (41)
Introduction to the special section: Myelin and oligodendrocyte abnormalities in schizophrenia. (2007) (41)
Patterns of cortical activity and memory performance in Alzheimer’s disease (2001) (41)
Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses. (1984) (40)
Convergent Findings for Abnormalities of the NF-κB Signaling Pathway in Schizophrenia (2013) (40)
Neurotransmitter metabolites in the cerebrospinal fluid of man following physostigmine. (1977) (40)
Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex (1993) (40)
Implications of multiple transmitter system lesions for cholinomimetic therapy in Alzheimer's disease. (1990) (40)
Localized cortical chronic traumatic encephalopathy pathology after single, severe axonal injury in human brain (2016) (39)
Choline chloride effects on memory in the elderly (1980) (39)
Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: Effects of typical neuroleptics on the brief psychiatric rating scale (1996) (38)
Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment (1998) (38)
The impact of behavioral impairment of functional ability in Alzheimer's disease (1999) (38)
Increased expression of receptor phosphotyrosine phosphatase-β/ζ is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes (2011) (38)
Correlates of lateral ventricular size in chronic schizophrenia, II: biological measures. (1986) (38)
The Caregiver Activity Survey (CAS): longitudinal validation of an instrument that measures time spent caregiving for individuals with Alzheimer's disease (2000) (37)
The cholinergic treatment strategy in aging and senile dementia. (1983) (37)
Prostaglandin receptor sensitivity in psychiatric disorders. (1986) (37)
Acute and chronic effects of neuroleptic drugs on plasma and brain homovanilic acid in the rat (1984) (36)
Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte-specific genes in individual thalamic nuclei (2008) (36)
The Effect of Citalopram Adjunctive Treatment Added to Atypical Antipsychotic Medications for Cognitive Performance in Patients With Schizophrenia (2005) (36)
Cholinomimetics and memory. The effect of choline chloride. (1980) (36)
The Neuropharmacology of Tardive Dyskinesia, Spontaneous Dyskinesia, and Other Dystonias (1982) (36)
Assessing changes in Alzheimer's disease: Memory and language. (1986) (35)
Familial schizophrenia and treatment response. (1987) (34)
Genetic control of apomorphine-induced climbing behavior in two inbred mouse strains (1984) (34)
Effects of the D-1 agonist SKF-38393, combined with haloperidol, in schizophrenic patients: A preliminary report (1989) (34)
Genetic epidemiological study of maternal and paternal transmission of Alzheimer's disease. (1999) (34)
Agitation and postdexamethasone cortisol levels in Alzheimer's disease. (1992) (34)
MONOAMINE METABOLITES IN CSF IN PSYCHIATRIC DISORDERS (1979) (34)
Lack of association between cortisol hypersecretion and nonsuppression on the DST in patients with Alzheimer's disease. (1994) (34)
Novel putative nonprotein‐coding RNA gene from 11q14 displays decreased expression in brains of patients with schizophrenia (2003) (33)
Kraepelinian and non-Kraepelinian schizophrenia subgroup differences in cerebral metabolic rate (2002) (33)
Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. (1997) (33)
Lateral ventricular enlargement in schizotypal personality disorder (1995) (33)
Memory impairment in schizophrenic patients with tardive dyskinesia (1988) (32)
Aggression in elderly schizophrenia patients: a comparison of nursing home and state hospital residents. (2001) (32)
Physostigmine: Effects on cognition and affect in normal subjects (1976) (32)
Pituitary response to thyrotropin-releasing hormone in depression. (1976) (31)
Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease (1995) (31)
Age at onset and familial risk in Alzheimer's disease. (1995) (30)
Kraepelinian schizophrenia: a subgroup of schizophrenia? (1988) (30)
l-Deprenyl and physostigmine for the treatment of Alzheimer's disease (1995) (30)
Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients (1991) (30)
Effects of cholinergic stimulation on pituitary hormone release (1982) (30)
A comprehensive analysis of verbal fluency deficit in geriatric schizophrenia. (2004) (29)
Early response to clozapine in schizophrenia. (1994) (29)
Working Memory Performance in Poor Outcome Schizophrenia: Relationship to Age and Executive Functioning (2004) (29)
Ventricular enlargement associated with linkage marker for schizophrenia-related disorders in one pedigree. (1996) (28)
Pharmacological Alleviation of Combined Cholinergic/Noradrenergic Lesion‐Induced Memory Deficits in Rats (1991) (28)
Elevated Alpha1-Antichymotrypsin Serum Levels in a Subset of Nondemented First-Degree Relatives of Alzheimer's Disease Patients (1995) (28)
Cerebrospinal fluid acetylcholine, choline, and senile dementia of the Alzheimer's type. (1982) (28)
Correlations post-mortem between ventricular CSF and cortical tissue concentrations of MHPG, 5-HIAA and HVA in Alzheimer's disease (1989) (27)
Partial reversal of anticholinergic amnesia by choline chloride. (1981) (27)
Cognitive burden and excess Lewy-body pathology in the Lewy-body variant of Alzheimer disease. (2003) (27)
Plasma homovanillic acid in schizotypal personality disorder. (1991) (27)
Induction of dopaminergic mesolimbic receptor supersensitivity by haloperidol. (1978) (27)
Cognitive assessment of geriatric schizophrenic patients with severe impairment. (2002) (27)
Validity and Stability of Performance-Based Estimates of Premorbid Educational Functioning in Older Patients with Schizophrenia (2006) (26)
Oral physostigmine in Alzheimer's disease. (1983) (26)
Interactions of forebrain cholinergic and somatostinergic systems in the rat (1989) (26)
A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease (1982) (25)
Adrenergic and serotonergic receptor responsiveness in depression. (1986) (24)
Linkage and Association of the Mitochondrial Aspartate / Glutamate Carrier SLC 25 A 12 Gene With Autism (2004) (24)
Experimental pharmacology of Alzheimer disease. (1983) (24)
Diminished prolactin responses to repeated fenfluramine challenge in man (1987) (23)
Apomorphine and schizophrenia. (1984) (23)
The use of cholinergic precursors in neuropsychiatric diseases. (1982) (23)
Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy (2011) (23)
Letter: EEGs of "binge" eaters. (1974) (22)
Alzheimer's disease (2000) (22)
Effects of propantheline bromide on basal growth hormone, cortisol and prolactin levels (1983) (22)
Coexisting tardive dyskinesia and parkinsonism: a case report. (1977) (22)
Statistical power in biological psychiatry (1981) (22)
Computer-administration of questionnaires: a health screening system (HSS) developed for veterans. (1996) (22)
Choline chloride in schizophrenia. (1979) (22)
Guidelines for the Appropriate Use of Cholinesterase Inhibitors in Patients with Alzheimer’s Disease (1999) (22)
A Risk-Benefit Assessment of Tacrine in the Treatment of Alzheimer’s Disease (1997) (22)
BACLOFEN IN SCHIZOPHRENIA (1976) (22)
Highly Sensitive and Simple Method for Determination of Free 3-Methoxy-4-Hydroxyphenylglycol in Plasma by High-Performance Liquid Chromatography Using a Sep-Pak Alumina B Cartridge (1988) (22)
Identifying families with likely genetic protective factors against Alzheimer disease. (1999) (21)
Strategies for the treatment of Alzheimer's disease (1993) (21)
Validity of the family history method for identifying schizophrenia-related disorders (1997) (21)
Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: Retrospective comparison of first generation and second generation antipsychotics (2006) (21)
Lack of Association between the Levels of the Low‐Density Lipoprotein Receptor‐Related Protein (LRP) and Either Alzheimer Dementia or LRP Exon 3 Genotype (2003) (21)
Clinical, cognitive and functional characteristics of long-stay patients with schizophrenia: a comparison of VA and state hospital patients (2000) (21)
Chronic administration of three neuroleptics: effects of behavioral supersensitivity mediated by two different brain regions in the rat. (1983) (21)
Brain Acetylcholine and Disorders of Memory (1979) (20)
Association of elevated alpha 1-antichymotrypsin with cognitive impairment in a prospective study of the very old. (1998) (20)
Experimental Approaches to Cognitive Disturbance in Alzheimer's Disease (1998) (20)
Biological markers in Alzheimer disease. (2002) (20)
Time course and clinical predictors of treatment response in schizophrenia (1991) (20)
Apolipoprotein E‐η4 allele and familial risk in Alzheimer's disease (1996) (20)
Research subject recruitment for gerontological studies of pharmacological agents (1982) (19)
Red blood cell choline. I: Choline in Alzheimer's disease (1985) (19)
Cortical and Subcortical Cognitive Deficits in Schizophrenia: Convergence of Classifications Based on Language and Memory Skill Areas (2002) (19)
Lecithin and piracetam in Alzheimer's disease (1987) (19)
Platelet alpha2-adrenergic receptor function in psychiatric disorders (1988) (18)
Central serotoninergic stimulation by fenfluramine challenge does not affect plasma thyrotropin-stimulating hormone levels in man. (1988) (18)
Gamma-hydroxybutyrate in the treatment of schizophrenia (1983) (18)
Plasma concentrations of choline in man following choline chloride. (1978) (17)
Interaction of choline and scopolamine in human memory. (1985) (17)
Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine (1994) (17)
Choline chloride effects on memory: Correlation with the effects of physostigmine (1980) (17)
Genetic antecedents of dopamine dysfunction in schizophrenia (1999) (17)
Psychobiology of personality disorders: pharmacologic implications. (1987) (17)
Effects of payment mode on clinic attendance and rehospitalization. (1977) (17)
Clinical correlates of platelet prostaglandin receptor subsensitivity in schizophrenia. (1987) (16)
Seasonality effects on schizophrenic births in multiplex families in a tropical island (2006) (16)
Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients (1985) (16)
Pisa syndrome in Alzheimer's disease (1988) (16)
A Pilot Study of Oral Physostigmine Plus Yohimbine in Patients with Alzheimer Disease (1993) (16)
Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems. (1985) (15)
Choline chloride in animal models of tardive dyskinesia. (1978) (15)
Neurofibrillary tangles, Alzheimer's disease, and Lewy bodies (1990) (15)
Alzheimerʼs disease: morbid risk among first-degree relatives approximates 50% by 90 years of age (1987) (15)
Development of an Institutionalized Chronic Alcoholic Scale. (1977) (15)
A study of the reliability of reported premorbid adjustment in schizophrenic patients. (1984) (14)
Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects (1992) (14)
Rapid High-Performance Liquid Chromatographic Determination of Physostigmine in Plasma (1982) (14)
Naloxone does not affect pain sensitivity, mood or cognition in patients with high levels of beta-endorphin in plasma. (1982) (14)
The role of prefrontal cortex in the dopaminergic dysregulation of schizophrenia. (1999) (14)
Impulsive aggression in personality disorder: Evidence for involvement of 5-HT-1 receptors (1989) (14)
Choline chloride in methylphenidate- and apomorphine-induced stereotypy. (1978) (14)
Dysregulation of the noradrenergic system in depression. (1984) (14)
in Patients With Alzheimer's Disease (1987) (14)
Studies of plasma homovanillic acid as an index of brain dopamine function. (1982) (14)
Apomorphine in schizophrenia. (1980) (14)
Red blood cell choline. II: Kinetics in alzheimer's disease (1985) (13)
Neurobiology of glutamatergic abnormalities in schizophrenia (2003) (13)
Integration of experimental and clinical precepts in memory assessment: A tribute to George Talland. (1986) (13)
Cyclic-AMP production by polymorphonuclear leukocytes in psychiatric disorders (1989) (13)
Convergent Findings for Abnormalities of the NF-κB Signaling Pathway in Schizophrenia (2013) (13)
Precursors of acetylcholine: considerations underlying their use in Tourette syndrome. (1982) (13)
Intracerebral des-tyrosine-γ-endorphin inhibits methylphenidate induced locomotor activity (1981) (13)
The lobotomist. (2008) (12)
Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. (1989) (12)
High-performance liquid chromatographic determination of tetrahydroaminoacridine in human and rat tissues using a rapid Sep-Pak C18 extraction. (1983) (12)
A pilot study of clonidine plus physostigmine in Alzheimer's disease. (1994) (12)
MSH and MIF-I in animal models of tardive dyskinesia (1980) (12)
Monitoring nortriptyline plasma concentrations. (1980) (11)
The Pathophysiology of the Schizophrenic Disorders : Perspective from the Spectrum By : (2004) (11)
Hormones in the Treatment of Psychiatric Disorders (1975) (11)
Deanol in tardive dyskinesia. (1977) (11)
Rapid antidepressant activity of melanocyte-inhibiting factor: a clinical trial. (1982) (11)
Eye tracking, schizophrenic symptoms, and schizotypal personality disorder (2005) (11)
Longitudinal changes: Cognitive, behavioral, and affective patterns in Alzheimer's disease. (1986) (11)
Peripheral myelin protein-22 is expressed in CNS myelin (2010) (11)
Neurofilament subunit protein abnormalities in the thalamus in schizophrenia (2004) (10)
Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics (2004) (10)
Prevalence and correlates of parkinsonism in an institutionalized population of geriatric patients with chronic schizophrenia (2000) (10)
Rapid Determination of Apomorphine in Brain and Plasma Using High-Performance Liquid Chromatography (1984) (10)
Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy (2011) (10)
Cholinergic drug effects on memory and cognition in humans. (1980) (10)
Endocrine changes in Alzheimer's disease. (1988) (10)
The Alzheimer’s Disease Assessment Scale: Modifications That Can Enhance its Use in Future Clinical Trials (1997) (10)
Future therapeutic approaches to Alzheimer's disease. (1998) (10)
Neurotransmitter Deficits in Alzheimer's Disease: Criteria for Significance (1983) (10)
Microarray database mining and cell differentiation defects in schizophrenia. (2011) (10)
Psychopharmacology: A Biochemical and Behavioral Approach (1978) (10)
Lack of association between clinical symptoms and postmortem indices of brain serotonin function in Alzheimer's disease (1995) (9)
133 Lateral ventricular enlargement in schizophrenic probands and their siblings with schizophrenia-related disorders (1997) (9)
Intravenous and Oral Physostigmine in Alzheimer’s Disease (1985) (9)
The effects of hypertension and body mass index on diffusion tensor imaging in schizophrenia (2011) (9)
NSAID and Alzheimer's disease; possible answers and new questions (2002) (9)
Acetylcholine and Anterior Pituitary Hormone Secretion (1979) (8)
Biological perspectives in chronic pain, depression, and organic mental disorders. (1981) (8)
A one-year double-blind comparison of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in patients with schizophrenia (2003) (8)
Post-mortem examination of dopaminergic parameters in Alzheimer's disease: Relationship to noncognitive symptoms (1993) (8)
Frontal functioning and plasma HVA in the relatives of schizophrenic patients (1992) (8)
Neuroendocrine dysfunction in Alzheimer's disease: results following TRH stimulation (1992) (8)
9-Amino-1,2,3,4-tetrahydroacridin-1-ols: Synthesis and Evaluation as Potential Alzheimer′s Disease Therapeutics. (1990) (7)
Growth hormone response to edrophonium in patients with Alzheimer's disease and normal control subjects. (1988) (7)
Correlation Between A x40 – , A x-42 – , and A x-43 – Containing Amyloid Plaques and Cognitive Decline (2002) (7)
Schizophrenia: a review of diagnostic and biological issues. II. Biological issues. (1983) (7)
Neurochemistry and neuropharmacology. (1988) (7)
Dementia in elderly schizophrenic patients (1991) (7)
Apolipoprotein E-epsilon 4 allele and familial risk in Alzheimer's disease. (1996) (7)
Instrument and data review: The quest for external validators. (1986) (7)
Pharmacological Treatment of Dementia: A Review (2003) (7)
Dopaminergic dysregulation in schizophrenia: A target for new drugs (1986) (7)
Issues and perspectives on brain tissue banking (2002) (6)
Has familial aggregation in Alzheimer's disease been overestimated? (2000) (6)
Human memory and the effects of physostigmine and choline chloride [proceedings]. (1980) (6)
Physostigmine in patients with Alzheimer's disease. (1986) (6)
ALZHEIMER'S DISEASE : SEEKING NEW WAYS TO PRESERVE BRAIN FUNCTION (1999) (6)
Induction of behavioral supersensitivity to apomorphine by DFP treatment. (1981) (6)
Morbid Risk to First Degree Relatives of Neuropathologically Confirmed Cases of Alzheimer's Disease (1992) (6)
Contrasts between the d2 test of attention and intelligence measures from a normative sample (1999) (6)
Endocrine changes in Alzheimer's disease. (1988) (6)
DST in depression is unaffected by altering the clock time of its administration (1983) (6)
Increasing public trust and confidence in psychiatric research. (1999) (6)
Cholinergic Dysfunction in Mania and Movement Disorders (1978) (6)
Anticholinergic dementia as a model of Alzheimer's disease. (1986) (5)
Effect of apomorphine infusion on plasma homovanillic acid in normal subjects. (1986) (5)
Effects of debrisoquin on plasma homovanillic acid concentration in schizophrenic patients. (1987) (5)
Pharmacological Investigations of Cholinergic Mechanisms in Schizophrenia and Manic Psychosis (1979) (5)
Cholinergic inhibition of methylphenidate-induced stereotypy: Oxotremorine (1978) (5)
Platelet phospholipid synthesis in Alzheimer's disease (1991) (5)
Electrophysiological Effects of Physostigminein Humans (1979) (5)
Cerebrospinal fluid acetylcholinesterase in neuropsychiatric disorders (1979) (5)
Continuing Education in Psychotherapy as a Method to Attract and Involve Voluntary Faculty in an Academic Department of Psychiatry (1992) (4)
Schizophrenia: a review of diagnostic and biological issues. I. Diagnosis and prognosis. (1983) (4)
Rapid liquid chromatographic determination of probenecid in human cerebrospinal fluid. (1981) (4)
Age dependent change of ventricular measures in schizophrenia: Cross-sectional analysis (1994) (4)
THERAPEUTICS OF ALZHEIMER'S DISEASE FOR CLINICAL & PRE CLINICAL ISSUES (1989) (4)
Fourteen – Central Nervous System Disorders in Aging (1990) (4)
Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects (1992) (4)
beta-Endorphin and schizophrenia. (1980) (4)
Practical Pharmacology for Alzheimer’s Disease (2016) (4)
Assessment of Cognition and Affective Symptoms in Dementia (1985) (4)
Studies on choline chloride in neuropsychiatric disease: human and animal data. (1978) (4)
Cholinergic Aspects of Tardive Dyskinesia: Human and Animal Studies (1980) (4)
Treatment of Huntington’s Disease and Tardive Dyskinesia with Choline Chloride (1979) (4)
Symptom severity and cognitive impairment in elderly schizophrenic patients (1993) (4)
Neurotransmitter Interactions and Responsivity to Cholinomimetic Agents (1992) (4)
Acute and chronic effects of neuroleptic drugs on plasma and brain homovanillic acid in the rat. (1984) (3)
Elevated amyloid β-peptides in brain: Correlation with cognitive decline (2000) (3)
Somatostatin and NPY deficits in schizophrenic cortex (1995) (3)
Schizophrenia-Associated Idiopathic Unconjugated Hyperbilirubinemia ( Gilbert ’ s Syndrome ) : 3 Case Reports (2003) (3)
Methodological issues in PET scan evaluation of dopamine supersensitivity in tardive dyskinesia (1989) (3)
Cholinomimetic Agents and Human Memory: Preliminary Observations in Alzheimer’s Disease (1981) (3)
Neuropathologic study of 101 elderly institutionalized schizophrenics (1995) (3)
The Treatment of Memory Deficits in the Aged with Choline Chloride (1979) (3)
Human and Animal Studies With Cholinergic Agents: How Clinically Exploitable is the Cholinergic Deficiency in Alzheimer’s Disease (1986) (3)
277. NMDA receptor dysregulation in schizophrenic prefrontal cortex (1998) (3)
Effects of indomethacin on plasma homovanillic acid concentration in normal subjects: a study of prostaglandin-dopamine interactions (2005) (3)
Convergence of cognitive and adaptive decline in chronic schizophrenia (1998) (3)
Galantamine for Alzheimer’s Disease and Alzheimer’s Disease with Cerebrovascular Disease (2016) (3)
Relationships between white matter metabolite abnormalities, cognitive and social functioning in elderly schizophrenic subjects (2008) (3)
Nucleus Basalis Lesions and Recovery (1991) (3)
A rationale for studying the transmissibility of Alzheimer's disease (1982) (3)
Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion (2004) (3)
Potential for Progress in the Therapeutics of Alzheimer’s Disease; Unanswered Questions (1997) (3)
Tacrine for Alzheimer's disease: a complex decision (1995) (3)
EEG effects of physostigmine and choline chloride in humans (1979) (3)
Cognitive Effects of Physostigmine and Choline Chloride in Normal Subjects (1979) (3)
Alzheimer's disease: Tacrine and tacrine metabolite concentrations in plasma and cognitive change (1995) (3)
Protecting research subjects and psychiatric research: we can do both. (1999) (3)
Butaclamol hydrochloride in newly admitted schizophrenics. (1975) (3)
Assessing Symptom Severity in Alzheimer’s Disease1 (1985) (3)
Choline Chloride: Effect on Hyperdopaminergic States in Animals (1979) (2)
Choline chloride in the treatment of Huntington's disease and tardive dyskinesia: a preliminary report. (1977) (2)
Plasma homovanillic acid concentrations decrease in responders, but not in non-responders, to neuroleptic treatment (1991) (2)
Risk of Alzheimer's Disease in First-Degree Relatives-Reply (1995) (2)
Letter: Bacloffen in schizophrenia. (1976) (2)
Progress in understanding the pathogenesis of Alzheimer's disease. (1996) (2)
Toward a therapeutic strategy based on amyloid precursor protein: Unanswered questions (1989) (2)
Pharmacokinetic Studies with Choline Chloride: A Preliminary Report (1979) (2)
DEMENTIA‐LIKE SYMPTOMS IN ELDERLY SCHIZOPHRENIC PATIENTS (1992) (2)
symptom correlates of poor eye tracking in patients with schizotypal personality disorder and relatives of schizophrenic probands (1989) (2)
Neuroimaging, neurobiological, and neuropsychological abnormalities in SPD: Implications for a model of the schizophrenia spectrum (1995) (2)
Special Issue: Molecular Mechanisms of Schizophrenia (2006) (2)
Elevated corticosteroids as a possible cause of abnormal neuroendocrine function in depressive illness. (1977) (2)
Structural brain differences between poor outcome and good outcome patients with schizophrenia (2003) (2)
Brain uptake indices of guanidine and 4-aminopyridine. (1984) (2)
Acute administration of alprazolam has no effect on plasma homovanillic acid concentration in normal subjects (1989) (2)
Animal Models of Multiple Neurotransmitter Interactions in Alzheimer's Disease (1995) (1)
MEASUREMENTS OF PLASMA HOMOVANILLIC ACID IN SCHIZOPHRENIC PATIENTS (1992) (1)
Serotonin receptor sensitivity in schizophrenia (1991) (1)
87 CURRENT AND EXPERIMENTAL THERAPEUTICS OF ALZHEIMER DISEASE (2002) (1)
The development of the young investigator (1991) (1)
405. Kainate receptor expression in postmortem schizophrenic brain (1998) (1)
Effects of famotidine, a histamine H2-receptor antagonist, on negative symptoms of schizophrenia (1991) (1)
229 Ionotropic glutamate receptor mRNA expression in schizophrenia (1997) (1)
Dr. Davis and Associates Reply (1980) (1)
Relations among eye tracking, CPT, and backward masking deficits in schizophrenic patients and their relatives (1989) (1)
A Simple Assay of 3-Methoxy-4-hydroxyphenylethyleneglycol in Cerebrospinal Fluid by High Performance Liquid Chromatography (1983) (1)
Noradrenergic and Serotonergic Dysfunction in the Affective Disorders (1989) (1)
Alzheimer's disease: seeking new ways to preserve brain function. Interview by Alice V. Luddington. (1999) (1)
Significant decrease in psychopathology within three days of haloperidol treatment in chronic schizophrenia (1992) (1)
Correlations between temporal lobe synaptic protein immunoactivity and schizophrenic psychosis (1995) (1)
Issues in Accelerating the Pace of Development for Neuroprotective Agents (1996) (1)
The relation between lisping and visual recognition memory in children (1972) (1)
Vulnerability and plasticity of monoamine neurotransmitter systems in affective and personality disorders (1990) (1)
Dimethylaminoethanol (Deanol): Effect on apomorphine-induced stereotypy and an animal model of tardive dyskinesia (1979) (1)
Chronobiological Dysregulation of the Noradrenergic System in Depression (1989) (1)
Antipsychotic Efficacy of Fluotracen: A Clinical Trial (1983) (1)
RNA profiling in neuropsychiatric disorders (1999) (1)
Intracerebral des-tyrosine-gamma-endorphin inhibits methylphenidate induced locomotor activity. (1981) (1)
ALZHEIMERʼS DISEASE AND RELATED NEURODEGENERATIVE DISEASES IN ELDERLY SCHIZOPHRENIC PATIENTS: A POST-MORTEM NEUROPATHOLOGIC STUDY OF 100 CASES. DP Purohit (1995) (1)
Treatment Of Alzheimer’s Disease (1990) (1)
ALZHEIMER AND OTHER DEMENTIAS (2002) (1)
Neuropsychological correlates of central monoamine function in schizophrenia (1993) (1)
Hypercortisolism and Brain Ventricular Size in Normal Aging and Alzheimer's Disease. (1994) (1)
Time course and clinical predictors of neuroleptic response in schizophrenia (1989) (1)
Kraepelinian schizophrenia: A replication in an independent sample (1991) (1)
PHYSOSTIGMINE INDUCED ALTERATIONS OF DOPAMINE METABOLITES IN CSF OF NORMAL SUBJECTS (1979) (1)
Comprar Practical Pharmacology For Alzheimer's Disease | Takashi Kudo | 9783319262048 | Springer (2016) (1)
Effect of chronic haloperidol and quinacrine coadministration on striatal HVA levels and stereotypic behaviors in response to apomorphine in the rat (1985) (1)
Cognitive and functional changes in older patients with schizophrenia: Evidence for cognitive threshold effects on functional decline? (2003) (1)
State and trait components of negative symptoms within schizophrenic patients (1989) (1)
Morbid Risk in First-Degree Relatives of Persons With Alzheimer's Disease-Reply (1988) (1)
Amyloid precursor protein inthecerebral cortex israpidly and persistently induced byloss ofsubcortical innervation (1993) (0)
Change in subtype presentation in schizophrenics. (1989) (0)
Commentary on review by gash et al. A clinical perspective on neural transplantation and potential applications to the aged brain (1985) (0)
Erratum: Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy (Neuropsychopharmacology (2011) 36 (1289-1295) DOI: 10.1038/npp.2011.14) (2011) (0)
News & notes (1990) (0)
Neuroleptic Treatment, Symptoms of Schizophrenia, and Plasma Homovanillic Acid Concentrations Revisited-Reply (1992) (0)
ORIGINAL ARTICLES i Neuropeptide Deficits in Schizophrenia Alzheimer's Disease Cerebral Cortex (1996) (0)
NEURONAL PERIKARYAL CONTRIBUTION TO THE DEVELOPMENT OF THE NEURITIC PLAQUE: EVALUATION THROUGH THE EXAMINATION OF PREFRONTAL CORTEX IN ELDERLY SCHIZOPHRENICS WHO UNDERWENT PREFRONTAL LEUKOTOMY (1993) (0)
VKučinskas-2001-2016 (2016) (0)
Psychopharmacology and neurotransmitter systems in the elderly (1981) (0)
WITHDRAWN: The Relationships Between White Matter Cerebral Metabolites and Clinical Manifestations in Geriatric Patients with Schizophrenia: A 4 Tesla Proton Magnetic Resonance Spectroscopy Study (2006) (0)
Phosphorylated cyclin dependent kinase 4-like-immunoreactivity is specifically expressed in vulnerable neurons of Alzheimers disease at its earliest (1998) (0)
Drs. Siever and Davis Reply (1986) (0)
Apolipoprotein E allele ϵ4 in autopsy-confirmed Alzheimer's disease and cerebrovascular disease (1994) (0)
EFFECT OF NEUROLEPTIC TREATMENT ON CSF MONOAMINE METABOLITES: RELEVANCE OF 5HT‐DA INTERACTIONS IN SCHIZOPHRENIA. (1992) (0)
30. Genetics of autism (2000) (0)
562. Indices of early dementia: neocortical levels of amyloid β-peptide (2000) (0)
Relatives of Schizophrenic (1994) (0)
Correlation between Aβ42 deposition and clinical demetia (2000) (0)
Dopamine receptor gene expression in postmortem human brain: An in situ hybridization study (1995) (0)
The characteristics of poor outcome, ‘Kraepelinian’ schizophrenia (1993) (0)
Improved sample preparation before liquid-chromatographic determination of probenecid in cerebrospinal fluid. (1983) (0)
543. Lateral and medial temporal Lobe metabolic rate in Alzheimer's disease (1996) (0)
Acceleration of the development of a treatment for Alzheimer's disease (1994) (0)
Time course and clinical predictors of neuroleptic response in schizophrenia (1989) (0)
Dopaminergic correlates of attentional performance in unmedicated schizophrenic patients (1992) (0)
Visuospatial working memory deficits in schizophrenia (1993) (0)
Clinical and neuroendocrine correlates of hypercortisolemia in Alzheimer's disease (1989) (0)
Alzheimer's disease cases with subcortical lewy bodies show diminished neocortical tangle formation (1989) (0)
Physostigmine Related Changes in Cerebrospinal Fluid Neurotransmitter Metabolites in Man (1979) (0)
BIOLOGICAL THERAPIES 31 . 15 CHOLINESTERASE INHIBITORS (2004) (0)
BIOLOGIC MARKERS IN DSM-III DIAGNOSED PERSONALITY DISORDERS (1984) (0)
Heterogeneity in undifferentiated schizophrenia (1989) (0)
Using family history screening for linkage studies in schizophrenia (1989) (0)
Alzheimer's and Parkinson's disease. New drug development, and innovative experimental approaches (1986) (0)
Response to Combination Cholinergic/Noradrenergic Treatments in a Patient With Alzheimer's Disease. (1993) (0)
A linkage marker for schizophrenia and related disorders (1994) (0)
Neuroimaging correlates of genetic marker for schizophrenia (1995) (0)
559. Current cogntive functioning versus premorbid status as predictors of levels of functioning (2000) (0)
A proton magnetic spectroscopy (1H MRS) study of possible white matter pathlolgy in schizophrenia (2003) (0)
30. Decreased levels of NMDAR1, GLUR1, GLUR7 and KA1 MRNAS in frontal cortex of schizophrenics (1998) (0)
Chronic Schizophrenia, II: Biological Measures (1986) (0)
PEr IPhEral My ElIn ProtEIn-22 Is Ex PrE ssE d In Cns My ElIn (2010) (0)
Processing and regional specificity of variant forms of the Alzheimer amyloid precursor protein (1989) (0)
RETRACTED: The Relationships Between White Matter Cerebral Metabolites and Clinical Manifestations in Geriatric Patients with Schizophrenia: A 4 Tesla Proton Magnetic Resonance Spectroscopy Study. (2006) (0)
Recent findings in Lewy body dementia (2000) (0)
Instruments for Measuring the Efficacy of Treatments for Alzheimer’s Disease (1994) (0)
A neuroimaging correlate for a schizophrenia-related genetic marker in one pedigree (1995) (0)
Medication enhances the development of automated information processing in schizophrenia (1989) (0)
Postmortem study of DA, 5HT, and their metabolites in cortex of schizophrenics and controls (1995) (0)
108. Neurocognitive predictors of functional decline in poor-outcome schizophrenia (2000) (0)
Effects of D1 agonist in schizophrenia (1989) (0)
Authors' response to commentaries on Hollander et al. antemortem marker paper (1986) (0)
Dr. Greenwald and Associates Reply (1987) (0)
84 Absence of neuropathological and neurochemical sequela of cognitive deficits in elderly schizophrenics (1997) (0)
Induction of APP results in its secretion and production of B-amyloid in subcortically lesioned rats (1994) (0)
248. Application of paradigms across illneses: Schizophrenia and Alzheimer's disease (1998) (0)
Responses to Clonidine in Acute and Remitted Depressed Patients (1986) (0)
Commentary on William Summers Paper on Tacrine March 6, 2000. (2000) (0)
(.+-.)-9-Amino-1,2,3,4-tetrahydroacridin-1-ol. A Potential Alzheimer′s Disease Therapeutic of Low Toxicity. (1988) (0)
Is very late onset Alzheimer's disease influenced by genetic factors? (2000) (0)
Glycinamide ribonucleotide synthetase activity in lymphocytes from patients with Alzheimer's disease and normal controls (1990) (0)
Possible clinical applications of laboratory tests in depression. (1984) (0)
Apolipoprotein ɛ4 allele and familial risk in Alzheimer's disease (1994) (0)
A comparison of ventricular size in familial versus sporadic schizophrenia (1995) (0)
Erratum: A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia (Biological Psychiatry 51:5 (349-357)) (2002) (0)
Abstract 53. Immunoglobulin Studies in psychiatric disease patients (1985) (0)
Caregiver Activity Survey (CAS) 1997 (2004) (0)
Cognitive impairment in Alzheimers disease and schizophrenia (1998) (0)
Screening of candidate genes related to myelination for mutations associated with schizophrenia (2001) (0)
[Cholinergic agents in the treatment of Alzheimer's disease]. (1987) (0)
369. Cognitive impairment in Alzheimer's disease and schizophrenia (1998) (0)
Optic nerve head in Alzheimer's disease patients (1989) (0)
Drs. Davis and Berger Reply (1982) (0)
Letter on “Ethical Problems in Psychiatric Research” (1998) (0)
Acute prenatal maternal stress and functional outcome in young adult life: A population based study (2003) (0)
Contents of The American Journal of Psychiatry (1987) (0)
Working memory dysfunction in Kraepelinian schizophrenics (1994) (0)
Contents of the American Journal of Psychiatry (2005) (0)
Dopamine receptor gene expression in postmortem brain in schizophrenia (1995) (0)
CHARACTERISTICS OF POOR OUTCOME SCHIZOPHRENIA (1992) (0)
187. Indices of early dementia (2000) (0)
Nocturnal growth hormone secretion in Schizophrenic patients and Healthy Subjects Lisa Webster, René S. Kahn, Michael Davidson, Jack Hirschowitz, Clare Moore, Kenneth L. Davis Mount Sinai School of Medicine, Bronx Veterans Administration Hospital, Bronx, NY 10468. (1992) (0)
Jack Peter Green, 1925–2007 (2007) (0)
Electrophysiological Effects of Choline Chloride in Elderly Subjects (1979) (0)
Age at first birth in women is genetically associated with increased risk of schizophrenia (2018) (0)
Drs. Aisen and Davis Reply (1995) (0)
Effects of chronic GM1 administration on transplant-induced reversal of memory impairments in nbm lesioned rats (1989) (0)
566. The temporal relationship of cognitive and functional decline in poor outcome schizophrenia (2000) (0)
Dementia in elderly schizophrenics (1992) (0)
Clinical predictors of exacerbation during neuroleptic discontinuation (1989) (0)
Biologic markers for personality disorders: A dimensional approach (1989) (0)
149. Verbal and physical aggression in poor outcome, geriatric schizophrenia (2000) (0)
560. Indices of early dementia: neuropathological indices (2000) (0)
Inflammatory Processes — Anti-Inflammatory Therapy (1997) (0)
Methodological issues in the pet scan evaluation of F-18 NMS binding in tardive dyskinesia (TD) (1989) (0)
ALPHA2 Adrenergic receptors in Alzheimer's disease and schizophrenic cortex frontal (1989) (0)
A reexamination of schizophrenia subtypes (1989) (0)
Effects of the D-1 agonist SKF-38393, combined with haloperidol, in schizophrenic patients: A preliminary report (1989) (0)
Cerebrospinal Fluid Acetylcholinesterase in Psychosis and Movement Disorders (1979) (0)
Apomorphine's Antipsychotic Activity-Reply (1985) (0)
2013 Daniel H. Efron Research Award (2012) (0)
Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy (2011) (0)
Morbid risk for definite schizophrenia In the first-degree relatives of paranoid , hebephrenic , and catatonic schizophrenics Study (2005) (0)
"Ethical problems in psychiatric research". (1998) (0)
Contents of The American Journal of Psychiatry (2004) (0)
The annual meeting of the society of biological psychiatry: President's message (1990) (0)
The Schizophrenia Biologic Research Centers of the Veterans Administration (1984) (0)
Effect of haloperidol on CSF monoamine metabolites in schizophrenia. Symptomatic improvement is related to altered dopamine-serotonin interaction (1992) (0)
Clinical investigations of plasma homovanillic acid concentrations (1990) (0)
A neurohistological study of elderly institutionalized schizophrenic and affective disorder patients (1994) (0)
218. Anti-inflammatory drug studies in Alzheimer's disease (1996) (0)
COGNITIVE EFFECfS OF PHYSOSTIGMINE AND CHOLINE CHWRIDE IN NORMAL SUBJECfS (1979) (0)
Nicotinic mechanisms: potential for therapeutic exploitation (2001) (0)
Neuroendocrine abnormalities in Alzheimer's disease: TRH test (1989) (0)
404. Thalamic glutamate receptor expression in schizophrenia (1998) (0)
Longitudinal classification in schizophrenia: The relationship between kraepelinian and deficit syndrome subtypologies (1994) (0)
Neuropeptides discriminate brains of schizophrenics from normals (1994) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kenneth L. Davis?

Kenneth L. Davis is affiliated with the following schools: